Skip to main content

Jennifer L. Cohen

Associate Professor of Pediatrics
Pediatrics, Medical Genetics

Overview


Jennifer L. Cohen, MD is an Associate Professor of Pediatrics in the Division of Medical Genetics. She has secondary appointments in Obstetrics and Gynecology and Molecular Genetics & Microbiology. She attended Yale College and then received her MD from the Icahn School of Medicine at Mount Sinai in NYC. She completed a combined residency program at the Children’s Hospital of Philadelphia in Pediatrics and Medical Genetics, before joining the faculty at Duke in 2019. Her research interests and expertise are in perinatal genetic medicine with a current focus on earlier diagnosis and management of rare genetic diseases. She is the physician lead for Pompe disease newborn screening in North Carolina and is actively involved in gene therapy clinical trials for lysosomal storage diseases. Dr. Cohen leads the Duke site for a clinical trial of prenatal enzyme replacement therapy for lysosomal storage diseases. Her long-time research interests and training have led her to pursue the study of in utero treatment for genetic diseases and to advance implementation of more rapid and comprehensive diagnostic testing in fetuses and critically ill infants.

Current Duke Appointments & Affiliations


Associate Professor of Pediatrics · 2025 - Present Pediatrics, Medical Genetics, Pediatrics
Associate Professor in Molecular Genetics and Microbiology · 2025 - Present Molecular Genetics and Microbiology, Basic Science Departments
Associate Professor in Obstetrics and Gynecology · 2025 - Present Obstetrics and Gynecology, Maternal Fetal Medicine, Obstetrics and Gynecology

Recent News Items


Published February 7, 2025
Artificial Womb Reduces Risks to Premature Babies
Published November 9, 2022
Duke Experts Participate in First Use of Fetal Therapy for Pompe Disease

View All News Items

Recent Scholarly Works


The Expanding Role of Gene Sequencing in Shaping Fetal Therapies: Clinical and Ethical Considerations.

Journal article Prenat Diagn · May 2026 In utero interventions are transformative in addressing genetic and anatomic conditions during fetal development. Next generation sequencing enables early genetic testing, playing a pivotal role in prenatal decision-making by supporting risk stratification ... Full text Link to item Cite

Early Initiation of Enzyme Replacement Therapy in Infantile Onset Pompe Disease Improves Cardiac Outcomes: A Longitudinal Analysis.

Journal article JIMD Rep · January 2026 The objective of this study is to evaluate whether early enzyme replacement therapy (ERT) initiation is associated with a lower incidence of echocardiogram abnormalities and cardiac conduction abnormalities compared to later ERT initiation. We identified a ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


Developing strategies to identify candidate individuals for early genetic therapies

ResearchPrincipal Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2024 - 2029

Phase 1 Study of In Utero Enzyme Replacement Therapy for the Treatment of Lysosomal Storage Diseases

ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2022 - 2027

View All Grants

Education


Icahn School of Medicine at Mount Sinai · 2015 M.D.